Revive Therapeutics (CSE: RVV) this morning provided an update on the status of its phase 3 clinical trial for the use of bucillamine in the treatment of mild to moderate Covid-19. The company, following its recent financing, is slated to significantly expand clinical sites involved in the ongoing study.
With the closing of the $23 million financing, the company is now looking to expand the clinical sites evaluating the use of bucillamine as outlined in the study. With 14 clinical sites involved in the trial, that figure is set to now expand to 50 sites to enable the company to reach the enrollment goals for the study in the second quarter of 2021.
The company is currently looking to perform interim analysis at the 210, 400, 600, and 800 completed patient time points. To date, no serious side effects have been reported in the study under the initial 210 patient time point. The company also revealed this morning that it intends to meet with the FDA in regards to applying for emergency use authorization upon completion of the review and recommendations of the Independent Data and Safety Monitoring Board.
“With our funding completed we are adding more clinical sites to meet our enrollment goals and be in a position to meet with the FDA to determine the best path forward for EUA approval. We are committed to achieving our mission in making Bucillamine the first orally administered drug to obtain FDA approval and EUA to treat mild to moderate COVID-19.”
Michael Frank, CEO of Revive Therapeutics
Revive Therapeutics last traded at $0.46 on the CSE.
Sponsored · Antimony Resources
FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
